Insight Molecular Diagnostics Inc. (IMDX) Form 10-Q — May 13, 2026
Insight Molecular Diagnostics Inc. (IMDX) reported a significant decline in net revenue for the quarter ended March 31, 2026, from $2,138,000 in the same period of 2025 to $32,000. This 98.5% decrease in revenue highlights the company's ongoing financial challenges. The company also reported a net loss of $4,290,000 for the quarter, compared to a net loss of $6,671,000 in the same period of 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 32
- Total Debt
- 0
- Cash Position
- 28201
- Shares Outstanding
- 32286
Price after filing
1 day: +25.9%7 days: +21.4%30 days: +6.5%
Close on the filing date to close N calendar days later (from $5.10). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.